Development of ImmTOR Tolerogenic Nanoparticles for the Mitigation of Anti-drug Antibodies.

ABSTRACT: The development of anti-drug antibodies (ADAs) is a common cause for treatment failure and hypersensitivity reactions for many biologics. The focus of this review is the development of ImmTOR, a platform technology designed to prevent the formation of ADAs that can be applied broadly across a wide variety of biologics by inducing immunological tolerance with ImmTOR nanoparticles encapsulating rapamycin. The induction of tolerance is antigen-specific and dependent on the incorporation of rapamycin in nanoparticles and the presence of the antigen at the time of administration of ImmTOR. Evidence for the induction of specific immune tolerance vs. general immune suppression is supported by the findings that: (1) ImmTOR induces regulatory T cells specific to the co-administered antigen; (2) tol

SUBMITTER: Kishimoto TK 

PROVIDER: S-EPMC7251066 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature